Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Aims Prostate cancer is one of the most frequent causes of cancer death in men worldwide,
and novel drugs for prostate cancer therapies are still being developed. Palmitic acid is a …

Prostate cancer (PCa) accounts for a high number of deaths in males with no available
curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to …

Simple Summary Apalutamide, darolutamide and enzalutamide are androgen-receptor
signaling inhibitors proved to be useful in patients with nonmetastatic castration-resistant …

Androgen deprivation therapy (ADT) is still a mainstay of treatment for advanced prostate
cancer. Continuous ADT causes considerable patient morbidity including sexual …

Purpose: This study provides a contemporary assessment of the treatment patterns, health
care resource utilization (HRU) and costs among metastatic castration-sensitive prostate …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Prostate cancer (PCa) is known as one of the most prevalent malignancies globally and is
not yet curable owing to its progressive nature. It has been well documented that Genetic …

Angiogenesis, the formation of new blood vessels, is an important stage in the growth of
cancer. Extracellular matrix, endothelial cells, and soluble substances must be carefully …